Interview with Ulrich Behrendt, President, VBU
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Address: Theodor-Heuss-Allee 25 D – 60486 Frankfurt am Main,Germany
Tel: 069 / 75 64- 124
VBU – Association of German Biotech Companies was founded in October 1996 on the initiative of 55 biotech companies. VBU now has over 210 corporate members, making it the largest and oldest industrial biotechnology association in Germany.Since its foundation VBU has devoted itself to the promotion of science and technology and the transfer of research findings into innovations. Furthermore VBU works in close collaboration with other national and international organisations from the areas of biotechnology, pharma, and knowledge and technology transfer.VBU is part of DECHEMA e.V. which was founded in 1926. Today DECHEMA has over 5,000 personal and sustaining members from science and industry.DECHEMA pools the know-how of experts, provides strong networks for research and development, is a platform for expert information, communication, and practice-oriented exchange of ideas and experience. DECHEMA is at the interface between science, industry, regulatory bodies and the public.
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country,…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
See our Cookie Privacy Policy Here
